The clinical trials of BET inhibitors were performed in patients with hematological malignancies (AML, lymphoma, myeloma, myelofibrosis) and solid tumors (prostate cancer, lung carcinoma, melanoma, breast cancer, sarcoma, NUT midline carcinoma). This evidence concerns the gene DNER and plasma cell myeloma.